The Launch Nobody Has Done Before

Every drug launch is hard. Rare disease launches are hard in a different way.

Here's the pattern I see most often. A company picks up an orphan asset late in development, often from a small biotech. It is new to the therapeutic area. Nobody in the affiliate has an analogue to copy. And the launch plan arrives as a template built for a specialty product with thousands of patients.

That template assumes patients are already diagnosed, access is a dossier you file after approval, and sales capacity is the main lever. In a rare disease, none of that is true.

What follows is how I think about an orphan launch in Europe, and specifically in Benelux, after more than two decades of doing them. Where something is my practitioner judgement rather than how the system works, I'll say so.

Why Big-Pharma Launch Models Break on Orphan Products

Three things break first.

Timing. Standard launches build country field teams six to twelve months out. For an orphan product that is too late: relationships with the few expert physicians and the patient organisation take longer, and access work starts before the label is final.

Working in silos. Medical, access and commercial each run their own plan. In a rare disease there may be three or four real experts in Belgium and a similar number in the Netherlands. If each function approaches them separately, with slightly different messages, you lose credibility in a month.

Sizing by forecast. A small patient number produces a small forecast, a small team and a small budget. But finding patients, building evidence, negotiating access and supporting families is more work per patient, not less.

This is why I don't see the four pillars below as a nice layer on top of the commercial plan. They are the commercial plan.

Pillar 1: Earn the Community Before You Need It

In most rare diseases, the people who know the patient journey best are not in your company. They are the patients and families, the patient organisation, and a small number of expert physicians, often working inside a European Reference Network or a national expertise centre.

You need basic answers first. How long from first symptoms to diagnosis? Which specialists does a patient see on the way? Where are the treating centres, and who decides? Market research won't tell you, because the sample doesn't exist.

Companies that do this well spend time with patients and caregivers long before there is anything to promote. They work with the patient organisation on what it actually needs: registries, needs surveys, trial design input, awareness work. They back expert physicians through investigator-initiated studies and registries that go beyond what the regulator asked for.

My practitioner view: this only works if it is genuine and sustained. Patient organisations in Benelux are small, well connected and have long memories. A company that shows up six months before launch and disappears after reimbursement will find the door closed for its next product. That is a commercial cost, even if it never appears in a forecast.

Pillar 2: Patient Finding Is the Market

In a common disease, the market exists and you compete for share. In a rare disease, the market often has to be found, one patient at a time.

Where diagnosis is simple, the job is mostly awareness: the right specialists need to think of the condition and know where to refer. Where diagnosis is hard, the job is bigger. In lysosomal storage disorders such as Fabry disease, for example, the industry has a long history of supporting access to diagnostic testing, often together with patient organisations and laboratories, because many patients were simply never tested.

Data helps too. Undiagnosed patients have no diagnosis code, but they do have a medical history. A patient with Gaucher disease may have a trail of visits for an enlarged spleen or liver, anaemia and low platelets long before anyone names the disease. With proper governance and de-identified data, that pattern shows which centres are most likely to have an undiagnosed patient. Field visits go there; everyone else gets lower-cost digital education. I wrote in March about how AI is starting to change rare disease diagnosis and monitoring, and patient finding is one of the most concrete uses.

In Benelux the practical version is more personal. The relevant centres can be mapped by name. Patient finding becomes a joint medical and commercial project: mapping referral routes into the expertise centres, supporting genetic testing pathways, and making sure the regional paediatrician, neurologist or nephrologist knows when to refer.

Pillar 3: Access Is Commercial Work, Not a Back-Office Task

Orphan drugs are expensive, and European payers want evidence beyond a small pivotal trial. That makes access the biggest driver of how fast an orphan launch generates revenue. Three things matter most.

Early access, planned as a bridge. Most European countries have some route for patients to get a product before reimbursement: compassionate use, medical need programmes, named-patient supply or post-trial access. In Belgium, compassionate use and medical need programmes run through the federal medicines agency (FAGG-AFMPS); in the Netherlands, named-patient supply through the hospital pharmacy is common. These programmes are good for patients, and they are also strategic choices: which countries you open, in what form, and how you move to reimbursed supply all shape your price negotiation. An early access programme without an exit plan is a commercial risk.

Shortening the gap between diagnosis and first dose. Even after reimbursement, getting a patient onto treatment can take months of formulary decisions, individual approvals and hospital budget questions. In Belgium, some patients depend on individual requests to the Special Solidarity Fund. Helping centres use these routes correctly and compliantly is real commercial work.

Planning for the HTA reality. Reimbursement still runs nationally, through RIZIV-INAMI in Belgium and the Zorginstituut and health ministry in the Netherlands. On top of that, the EU joint clinical assessment under the HTA Regulation is being phased in, and orphan medicinal products are in scope. My view: orphan teams should already be planning their evidence as if a joint assessment will be read alongside every national dossier, because the comparator and endpoint choices made now will follow the product for years.

The full sequence is on our page on orphan drug launch in Europe.

Pillar 4: Support Keeps Patients on Therapy

Rare disease patients discontinue for clinical and psychological reasons. Treatment can be burdensome, and families are often exhausted by years of searching for a diagnosis.

Good support means nurse services, home infusion where relevant, education for families and clear contact points for the treating centre. In the US, companies often run these services directly. In Europe, direct company-to-patient contact is far more restricted, so support usually runs through a third-party provider, the hospital or the patient organisation, under clear compliance rules.

Commercially, support is not a cost line to cut. Every patient who stays on therapy protects revenue, and what you learn feeds the next conversation with physicians and payers, and your real-world evidence.

Making It Work: Team, Timing and Evidence

One team, not three functions

An orphan launch team works as one unit: a shared log of every contact with experts and the patient organisation, one account plan per expert centre, clear rules on who leads which conversation. Medical leads on science, access on payers and hospital procedures, commercial field on the centre as a whole: referral routes, logistics, the hospital pharmacy.

The roles are familiar (medical, access, commercial field, regional hub), but the people need to be broader. A rare disease commercial field lead has to understand access, speak credibly about the science and know when to let medical lead.

Start early, in the right order

My practitioner rule of thumb: medical starts first, around 15 to 18 months before launch, to build relationships with experts and the patient community. Access follows a few months later, because payer work in Europe starts well before approval. Analytics and marketing come next. The commercial field team can start closer to launch, but not so close that they can't learn the centres.

Don't duplicate the big-country model in small countries

The biggest mistake I see in Benelux is a company trying to copy a full big-country team into a small affiliate, or the opposite: covering Belgium and the Netherlands from a distant regional office with nobody local. Neither works.

What works is a small local core, a commercial lead plus medical and access capacity who know the system, backed by a regional hub for analytics, supply, regulatory and marketing. The local core is what can't be outsourced: expert relationships, payer conversations, hospital procedures.

This is where interim leadership often makes sense. A company entering Benelux, or a biotech launching its first European product, rarely needs a permanent country organisation on day one. It needs someone who has done it before to set up the launch, open the access route and hand over a working affiliate. That is the work we do with an interim Commercial Director for rare disease launches in Benelux.

Treat real-world evidence as part of the revenue plan

European payers often reimburse orphan products with conditions: managed entry agreements, registries, reassessment after a few years. Post-launch evidence decides whether the product keeps its price.

The logic is simple: define the value you need to prove, the data that supports it, and the registry or Phase IV study that produces it. Execution is where it goes wrong. Is data entry workable for a busy centre? Can physicians measure what the protocol asks for in daily practice? Do research partner contracts reward good data for years, not just study start-up? Design flaws often surface only at reassessment, when it is too late.

My view: real-world evidence belongs in the commercial plan, with a commercial owner, alongside medical. It is how you defend the business three years after launch.

What This Means in Practice

If you are preparing an orphan launch in Europe or Benelux, here is where I would start:

  1. Map the patient ecosystem by name. In Benelux this is a list, not a segmentation.
  2. Start medical and access early. If access starts at approval, you are late.
  3. Plan early access with an exit to reimbursed supply.
  4. Build one team with one account plan per expert centre.
  5. Size for the work, not the forecast.
  6. Give real-world evidence a commercial owner.

None of this is new to people who have launched orphan products. It is still not the default in many companies, and the gap between a template launch and a well-run one is measured in years of delayed access, and in patients who wait longer than they should.